Company news

Memphasys Ltd news in 2024

Memphasys Ltd's news releases, calls and decks from 2024, newest first.

View company

Bovine Study commences to assess RoXsta antioxidant system

December 19, 2024

Felix Clinical Registration Study completed, expanding mkt

December 17, 2024

Letter of Intent with Heranova for Felix System Distribution

December 11, 2024

Order for Felix System to Evaluate Suitability in UAE

December 4, 2024

RoXsta System's Potential in Cattle Breeding being Explored

December 4, 2024

Felix Clinical Trial Reaches 95% Completion

November 17, 2024

RoXsta System Secures Provisional Patent Approval

November 14, 2024

Completion of Placement and SPP offer

November 5, 2024

MEM Investor Presentation

October 25, 2024

Felix Trial registration update

October 24, 2024

Equine study commences with 12mth commercialisation expected

October 17, 2024

Prospectus

September 20, 2024

Short term loan facility

September 17, 2024

Positive initial study results - Felix equine application

September 15, 2024

Reinstatement to Official Quotation

September 12, 2024

A$2 million capital raising

September 12, 2024

Voluntary Suspension

September 10, 2024

Response to ASX Query

September 6, 2024

Equine fertility study positions Felix as leading technology

September 3, 2024

Felix sales clinical trial and Oxidative Stress devel update

July 23, 2024

Animal activity update - oxidative stress measurement system

July 19, 2024

Dr David Ali appointed full-time Chief Executive Officer

June 5, 2024

Investor Presentation

May 21, 2024

Felix Japanese trial provides sperm preparation benefits

May 20, 2024

2024 Investor Presentation

May 9, 2024

Felix TM System Sales Orders Accelerate in Japan

March 17, 2024

AI-Port Update - Spring Field Trial Yields Positive Results

January 24, 2024

Vitrolife distribution agreement expands into Canada and NZ

January 1, 2024

Decks in 2024